Table 1. Clinical trials involving targeted agents for RCC.

Agent	No. of patients	Overall responsea (%)	Time to progression (months)
Sunitinib
Phase II	63	40	8.7
Sorafenib
Phase III	335	2	6.0
Bevacizumab
High-dose arm	39	10	4.8 (P<0.001 vs placebo)
Bevacizumab and erlotinib	59	25	11.1
CCI-779 and IFNα	71	11	9.1

^aSummation of partial and complete response based on response evaluation criteria in solid tumours (RECIST).